An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity

Science Translational Medicine

Volumn 4, Issue 153, 2012, Pages

  Ottoboni, Linda ^a,b,c   Keenan, Brendan T ^a,c   Tamayo, Pablo ^c   Kuchroo, Manik ^a   Mesirov, Jill P ^c   Buckle, Guy J ^b,d   Khoury, Samia J ^b,d   Hafler, David A ^c,e   Weiner, Howard L ^b,d   De Jager, Philip L ^a,b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; RNA; TRANSCRIPTOME;

ADULT; ARTICLE; DEMYELINATION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IFI44 GENE; IFI44L GENE; IFI6 GENE; IFIT GENE; IFIT1 GENE; IFIT2 GENE; INTRACELLULAR SIGNALING; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MX1 GENE; OAS1 GENE; OAS2 GENE; OASL GENE; PRIORITY JOURNAL; RNA ANALYSIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ADULT; CLUSTER ANALYSIS; DEMOGRAPHY; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERFERON-BETA; LIKELIHOOD FUNCTIONS; MALE; MOLECULAR SEQUENCE ANNOTATION; MULTIPLE SCLEROSIS; PEPTIDES; RNA; TRANSCRIPTOME;

EID: 84866871850     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004186     Document Type: Article

References (26)

1. S. L. Hauser, J. R. Oksenberg, The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron 52, 61-76 (2006).
2. P. A. Brex, J. I. O'Riordan, K. A. Miszkiel, I. F. Moseley, A. J. Thompson, G. T. Plant, D. H. Miller, Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53, 1184-1190 (1999).
3. C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. A. Panzara, A. W. Sandrock; AFFIRM Investigators, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
4. L. Kappos, E. W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L. Zhang-Auberson, P. Burtin; FREEDOMS Study Group, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010).
5. J. C. Corvol, D. Pelletier, R. G. Henry, S. J. Caillier, J. Wang, D. Pappas, S. Casazza, D. T. Okuda, S. L. Hauser, J. R. Oksenberg, S. E. Baranzini, Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc. Natl. Acad. Sci. U.S.A. 105, 11839-11844 (2008).
6. S. E. Baranzini, P. Mousavi, J. Rio, S. J. Caillier, A. Stillman, P. Villoslada, M. M. Wyatt, M. Comabella, L. D. Greller, R. Somogyi, X. Montalban, J. R. Oksenberg, Transcription-based prediction of response to IFNb using supervised computational methods. PLoS Biol. 3, e2 (2005).
7. M. K. Singh, T. F. Scott, W. A. LaFramboise, F. Z. Hu, J. C. Post, G. D. Ehrlich, Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing β-interferon therapy. J. Neurol. Sci. 258, 52-59 (2007).
8. R. H. Goertsches, U. K. Zettl, M. Hecker, Sieving treatment biomarkers from blood gene-expression profiles: A pharmacogenomic update on two types of multiple sclerosis therapy. Pharmacogenomics 12, 423-432 (2011).
9. M. Comabella, J. D. Lünemann, J. Río, A. Sánchez, C. López, E. Julià, M. Fernández, L. Nonell, M. Camiña-Tato, F.Deisenhammer, E. Caballero, M. T. Tortola, M. Prinz, X. Montalban, R. Martin, A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis. Brain 132, 3353-3365 (2009).
10. R. A. Rudick, M. R. Rani, Y. Xu, J. C. Lee, J. Na, J. Shrock, A. Josyula, E. Fisher, R. M. Ransohoff, Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One 6, e19262 (2011).
11. J. P. Brunet, P. Tamayo, T. R. Golub, J. P. Mesirov, Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. U.S.A. 101, 4164-4169 (2004).
12. R. Rifkin, S. Mukherjee, P. Tamayo, S. Ramaswamy, C.-H. Yeang, M. Angelo, M. Reich, T. Poggio, E. S. Lander, T. R. Golub, J. P. Mesirov, An analytical method for multiclass molecular cancer classification. SIAM Rev. 45, 706-723 (2003).
13. T. Evgeniou, M. Pontil, T. Poggio, Regularization networks and support vector machines. Adv. Comput. Math. 13, 1-50 (2000).
14. M. Reich, T. Liefeld, J. Gould, J. Lerner, P. Tamayo, J. P. Mesirov, GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).
15. R. Gross, B. C. Healy, S. Cepok, T. Chitnis, S. J. Khoury, B. Hemmer, H. L. Weiner, D. A. Hafler, P. L. De Jager, Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J. Neuroimmunol. 233, 168-174 (2011).
16. S. J. Khoury, C. R. Guttmann, E. J. Orav, M. J. Hohol, S. S. Ahn, L. Hsu, R. Kikinis, G. A. Mackin, F. A. Jolesz, H. L. Weiner, Longitudinal MRI in multiple sclerosis: Correlation between disability and lesion burden. Neurology 44, 2120-2124 (1994).
17. S. A. Gauthier, B. I. Glanz, M. Mandel, H. L. Weiner, A model for the comprehensive investigation of a chronic autoimmune disease: The multiple sclerosis CLIMB study. Autoimmun. Rev. 5, 532-536 (2006).
18. C. H. Polman, S. C. Reingold, G. Edan, M. Filippi, H. P. Hartung, L. Kappos, F. D. Lublin, L. M. Metz, H. F. McFarland, P. W. O'Connor, M. Sandberg-Wollheim, A. J. Thompson, B. G. Weinshenker, J. S. Wolinsky, Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58, 840-846 (2005).
19. D. D. Lee, H. S. Seung, Learning the parts of objects by non-negative matrix factorization. Nature 401, 788- 791 (1999).
20. D. D. Lee, H. S. Seung, Algorithms for non-negative matrix factorization. Adv. Neural Inf. Process. Syst. 13, 556-562 (2001).
21. G. K. Smyth, Limma: Linear models for microarray data, in Bioinformatics and Computational Biology Solutions using R and Bioconductor, R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber, Eds. (Springer, New York, 2005), pp. 397-420.
22. P. L. De Jager, L. B. Chibnik, J. Cui, J. Reischl, S. Lehr, K. C. Simon, C. Aubin, D. Bauer, J. F. Heubach, R. Sandbrink, M. Tyblova, P. Lelkova; Steering Committee of the BENEFIT Study; Steering Committee of the BEYOND Study; Steering Committee of the LTF Study; Steering Committee of the CCR1 Study; E. Havrdova, C. Pohl, D. Horakova, A. Ascherio, D. A. Hafler, E. W. Karlson, Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol. 8, 1111-1119 (2009).
23. C. Fraley, A. E. Raftery, Model-based clustering, discriminant analysis, and density estimation. J. Am. Stat. Assoc. 97, 611-631 (2002).
24. C. Fraley, A. E. Raftery, MCLUST Version 3 for R: Model Mixture Modeling and Model-Based Clustering (Technical Report no. 504, Department of Statistics, Washington, 2006).
25. I. T. Jolliffe, Principal Component Analysis (Springer, New York, 2nd ed., 2002).
26. T. M. Therneau, P. M. Grambsch. Modeling Survival Data: Extending the Cox Model (Springer, New York, 1st ed., 2000).